Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 6915912, 14 pages
https://doi.org/10.1155/2017/6915912
Research Article

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma

1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China
2Department of Immunology, Binzhou Medical University, Yantai, Shandong 264003, China
3Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, China

Correspondence should be addressed to Huizhong Li; nc.ude.umhzx@zhl and Junnian Zheng; nc.ude.umhzx@gnehznj

Received 7 August 2017; Revised 17 September 2017; Accepted 8 October 2017; Published 20 December 2017

Academic Editor: Rosa Molfetta

Copyright © 2017 Qing Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Kuusk, N. Grivas, R. de Bruijn, and A. Bex, “The current management of renal cell carcinoma,” Minerva Medica, vol. 108, no. 4, pp. 357–369, 2017. View at Publisher · View at Google Scholar
  2. W. M. Linehan and C. J. Ricketts, “Kidney cancer in 2016: RCC—advances in targeted therapeutics and genomics,” Nature Reviews Urology, vol. 14, no. 2, pp. 76–78, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. G. D. Stewart, M. De Santis, B. Escudier, T. Powles, and G. Sonpavde, “Immunotherapy for renal cancer: sequencing and combinations,” European Urology Focus, vol. 2, no. 6, pp. 582–588, 2016. View at Publisher · View at Google Scholar
  4. K. G. Liu, S. Gupta, and S. Goel, “Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects,” Oncotarget, vol. 8, no. 10, pp. 17313–17327, 2017. View at Publisher · View at Google Scholar
  5. C. U. Louis, B. Savoldo, G. Dotti et al., “Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma,” Blood, vol. 118, no. 23, pp. 6050–6056, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Pule, B. Savoldo, G. D. Myers et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma,” Nature Medicine, vol. 14, no. 11, pp. 1264–1270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. E. Brown, D. Alizadeh, R. Starr et al., “Regression of glioblastoma after chimeric antigen receptor T-cell therapy,” New England Journal of Medicine, vol. 375, no. 26, pp. 2561–2569, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. R. P. Junghans, Q. Ma, R. Rathore et al., “Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response,” The Prostate, vol. 76, no. 14, pp. 1257–1270, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. C. H. Lamers, Y. Klaver, J. W. Gratama, S. Sleijfer, and R. Debets, “Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview,” Biochemical Society Transactions, vol. 44, no. 3, pp. 951–959, 2016. View at Publisher · View at Google Scholar
  10. M. Holubova, M. Miklikova, M. Leba et al., “Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study,” Journal of Cancer Research and Clinical Oncology, vol. 142, no. 12, pp. 2561–2567, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Gong, G. Maki, and H. G. Klingemann, “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells,” Leukemia, vol. 8, no. 4, pp. 652–658, 1994. View at Google Scholar
  12. S. Arai, R. Meagher, M. Swearingen et al., “Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial,” Cytotherapy, vol. 10, no. 6, pp. 625–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Muller, C. Uherek, G. Maki et al., “Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells,” Cancer Immunology, Immunotherapy, vol. 57, no. 3, pp. 411–423, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Boissel, M. Betancur, W. S. Wels, H. Tuncer, and H. Klingemann, “Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells,” Leukemia Research, vol. 33, no. 9, pp. 1255–1259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Esser, T. Muller, D. Stefes et al., “NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin,” Journal of Cellular and Molecular Medicine, vol. 16, no. 3, pp. 569–581, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Sahm, K. Schonfeld, and W. S. Wels, “Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor,” Cancer Immunology, Immunotherapy, vol. 61, no. 9, pp. 1451–1461, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Zhang, M. C. Burger, L. Jennewein et al., “ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma,” Journal of the National Cancer Institute, vol. 108, no. 5, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Schonfeld, C. Sahm, C. Zhang et al., “Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor,” Molecular Therapy, vol. 23, no. 2, pp. 330–338, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Chu, Y. Deng, D. M. Benson et al., “CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma,” Leukemia, vol. 28, no. 4, pp. 917–927, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Jiang, W. Zhang, P. Shang et al., “Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells,” Molecular Oncology, vol. 8, no. 2, pp. 297–310, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Han, J. Chu, W. Keung Chan et al., “CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells,” Scientific Reports, vol. 5, no. 1, article 11483, 2015. View at Google Scholar
  22. S. Genssler, M. C. Burger, C. Zhang et al., “Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival,” Oncoimmunology, vol. 5, no. 4, article e1119354, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. K. H. Chen, M. Wada, A. E. Firor et al., “Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies,” Oncotarget, vol. 7, no. 35, pp. 56219–56232, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. K. H. Chen, M. Wada, K. G. Pinz et al., “Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor,” Leukemia, vol. 31, no. 10, pp. 2151–2160, 2017. View at Publisher · View at Google Scholar
  25. X. Chen, J. Han, J. Chu et al., “A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases,” Oncotarget, vol. 7, no. 19, pp. 27764–27777, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. Q. Zhang, H. Li, J. Yang et al., “Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer,” Current Gene Therapy, vol. 13, no. 1, pp. 65–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Scarfo and M. V. Maus, “Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment,” Journal for ImmunoTherapy of Cancer, vol. 5, no. 1, p. 28, 2017. View at Publisher · View at Google Scholar
  28. D. H. Munn, M. D. Sharma, T. S. Johnson, and P. Rodriguez, “IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment,” Cancer Immunology, Immunotherapy, vol. 66, no. 8, pp. 1049–1058, 2017. View at Publisher · View at Google Scholar
  29. K. K. Goswami, T. Ghosh, S. Ghosh, M. Sarkar, A. Bose, and R. Baral, “Tumor promoting role of anti-tumor macrophages in tumor microenvironment,” Cellular Immunology, vol. 316, pp. 1–10, 2017. View at Publisher · View at Google Scholar
  30. J. Zhou, Y. Yao, Q. Shen, G. Li, L. Hu, and X. Zhang, “Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells,” Journal of Cancer Research and Clinical Oncology, vol. 143, no. 8, pp. 1371–1380, 2017. View at Publisher · View at Google Scholar
  31. J. Hu, S. Zhu, X. Xia, L. Zhang, E. S. Kleinerman, and S. Li, “CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors,” Molecular Cancer, vol. 13, no. 1, p. 34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Alizadeh, M. Trad, N. T. Hanke et al., “Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer,” Cancer Research, vol. 74, no. 1, pp. 104–118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. J. S. Ko, A. H. Zea, B. I. Rini et al., “Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients,” Clinical Cancer Research, vol. 15, no. 6, pp. 2148–2157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. H. Finke, B. Rini, J. Ireland et al., “Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients,” Clinical Cancer Research, vol. 14, no. 20, pp. 6674–6682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Busse, A. M. Asemissen, A. Nonnenmacher et al., “Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma,” European Journal of Cancer, vol. 47, no. 5, pp. 690–696, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Cabrera, M. Ararat, Y. Xu et al., “Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma,” Cancer Immunology, Immunotherapy, vol. 62, no. 4, pp. 737–746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda, “Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity,” Clinical Cancer Research, vol. 11, no. 18, pp. 6713–6721, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. S. K. Bunt, A. M. Mohr, J. M. Bailey, P. M. Grandgenett, and M. A. Hollingsworth, “Rosiglitazone and gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer,” Cancer Immunology, Immunotherapy, vol. 62, no. 2, pp. 225–236, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Homma, K. Taniguchi, M. Nakazawa et al., “Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer,” Clinical and Translational Oncology, vol. 16, no. 3, pp. 330–335, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. F. T. Hsu, T. C. Chen, H. Y. Chuang, Y. F. Chang, and J. J. Hwang, “Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice,” Oncotarget, vol. 6, no. 42, pp. 44134–44150, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Matsushita, Y. Enomoto, H. Kume et al., “A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma,” Journal for ImmunoTherapy of Cancer, vol. 2, no. 1, p. 30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Takahara, S. Koido, M. Ito et al., “Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response,” Cancer Immunology, Immunotherapy, vol. 60, no. 9, pp. 1289–1297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Abdelaziz and U. Vaishampayan, “Cabozantinib for renal cell carcinoma: current and future paradigms,” Current Treatment Options in Oncology, vol. 18, no. 3, p. 18, 2017. View at Publisher · View at Google Scholar
  44. A. R. Kwilas, A. Ardiani, R. N. Donahue, D. T. Aftab, and J. W. Hodge, “Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine,” Journal of Translational Medicine, vol. 12, no. 1, p. 294, 2014. View at Google Scholar
  45. A. Patnaik, K. D. Swanson, E. Csizmadia et al., “Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity,” Cancer Discovery, vol. 7, no. 7, pp. 750–765, 2017. View at Publisher · View at Google Scholar
  46. X. Lu, J. W. Horner, E. Paul et al., “Effective combinatorial immunotherapy for castration-resistant prostate cancer,” Nature, vol. 543, no. 7647, pp. 728–732, 2017. View at Publisher · View at Google Scholar
  47. D. Balin-Gauthier, J. P. Delord, P. Rochaix et al., “In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR,” Cancer Chemotherapy and Pharmacology, vol. 57, no. 6, pp. 709–718, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Deng, J. Xiong, X. Gu et al., “Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro,” Oncotarget, vol. 8, no. 24, pp. 38568–38580, 2017. View at Publisher · View at Google Scholar
  49. R. Kurzrock, S. I. Sherman, D. W. Ball et al., “Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer,” Journal of Clinical Oncology, vol. 29, no. 19, pp. 2660–2666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. P. J. Neeson, A. K. Hsu, Y. R. Chen et al., “Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib,” Oncoimmunology, vol. 4, no. 9, article e1038011, 2015. View at Google Scholar
  51. W. Hu, R. R. Zheng, H. X. Cui, D. Yue, Y. Wang, and Y. H. Jiang, “Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity,” Asian Journal of Andrology, vol. 14, no. 5, pp. 695–702, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Gambacorti-Passerini, J. A. Hank, M. R. Albertini et al., “A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer,” Journal of Immunotherapy, vol. 13, no. 1, pp. 43–48, 1993. View at Publisher · View at Google Scholar
  53. R. I. Fisher, C. A. Coltman Jr., J. H. Doroshow et al., “Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial,” Annals of Internal Medicine, vol. 108, no. 4, pp. 518–523, 1988. View at Publisher · View at Google Scholar
  54. D. Wang, B. Zhang, H. Gao et al., “Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer,” BMC Cancer, vol. 14, no. 1, p. 251, 2014. View at Google Scholar
  55. A. Marten, E. Sievers, P. Albers et al., “Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma,” German Medical Science, vol. 4, article Doc02, 2006. View at Google Scholar
  56. C. H. Lamers, S. Sleijfer, A. G. Vulto et al., “Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience,” Journal of Clinical Oncology, vol. 24, no. 13, pp. e20–e22, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. C. H. Lamers, S. C. Langeveld, C. M. Groot-van Ruijven, R. Debets, S. Sleijfer, and J. W. Gratama, “Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo,” Cancer Immunology, Immunotherapy, vol. 56, no. 12, pp. 1875–1883, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Nguyen, J. Holland, D. Ramies et al., “Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib,” Journal of Clinical Pharmacology, vol. 56, no. 9, pp. 1130–1140, 2016. View at Publisher · View at Google Scholar · View at Scopus